Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 5/20 | 0.69 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | GCG | P01275 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 4/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592523 | 0.82 | XPO1 (1.00) | XPO1MCHR1CXCR3GCGPIM1 | |
| SCHEMBL1592364 | 0.81 | XPO1 (0.46) | XPO1PIM1PARP1 | |
| SCHEMBL1592405 | 0.76 | L3MBTL1 (0.50) | XPO1 | |
| SCHEMBL1592551 | 0.73 | XPO1 (0.38) | XPO1 | |
| SCHEMBL5365123 | 0.72 | XPO1 (0.56) | XPO1MCHR1GCGAR | |
| SCHEMBL1592924 | 0.71 | DYRK1A (0.38) | XPO1PARP1 | |
| SCHEMBL4992537 | 0.69 | XPO1 (0.68) | XPO1 | |
| SCHEMBL8133027 | 0.69 | XPO1 (0.53) | XPO1MCHR1GCGAR | |
| SCHEMBL2848264 | 0.66 | XPO1 (0.54) | XPO1AR | |
| SCHEMBL18434270 | 0.65 | RAB9A (0.55) | XPO1PIM1PIM2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152692-B9 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2020-03-25 | — | — | EP | claimed |
| EP-2152692-B1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2016-06-15 | — | — | EP | claimed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | claimed |
| US-8084454-B2 | Cell cycle G2-checkpoint-abrogating 1-[(2-pyridyl)amino]-azoline-2,5-dione derivatives with at least one halogen group, to selectively sensitize cancer cells to DNA damaging reagents without additional anticarcinogenic treatment; cytolytic agents, antiproliferatives, apoptosis | CANBAS CO., LTD. (JP) | 2011-12-27 | — | — | US | claimed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2152692-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | Canbas Co. Ltd. (JP) | 2010-02-17 | — | — | EP | claimed |
| WO-2009031040-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2009-03-12 | — | — | WO | claimed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4074704-A1 | QUINOLINE COMPOUNDS WITH ANTI-CANCER ACTIVITY | CanBas Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| EP-2152692-B9 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2020-03-25 | — | — | EP | disclosed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-B1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8084454-B2 | Cell cycle G2-checkpoint-abrogating 1-[(2-pyridyl)amino]-azoline-2,5-dione derivatives with at least one halogen group, to selectively sensitize cancer cells to DNA damaging reagents without additional anticarcinogenic treatment; cytolytic agents, antiproliferatives, apoptosis | CANBAS CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2152692-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | Canbas Co. Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009031040-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2009-03-12 | — | — | WO | disclosed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | XPO1 280/4885MCHR1 3531/4885CXCR3 2052/4885 |
| US-20080275057-A1 | Compounds with anti-cancer activity | CDKN1A, CDC25C, DDB1 | XPO1 280/4885MCHR1 3531/4885CXCR3 2052/4885 |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | MAVS, DDX18, ZC3HAV1 | XPO1 302/4885MCHR1 4018/4885CXCR3 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.